Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
June 18, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint...
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
June 10, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
May 08, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
May 07, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024...
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
April 30, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 24, 2024 16:01 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Intra-Cellular Therapies Prices Public Offering of Common Stock
April 17, 2024 20:46 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
April 16, 2024 16:06 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization...